• Consensus Rating: Buy
  • Consensus Price Target: $8.67
  • Forecasted Upside: 20.87%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$7.17
▲ +0.1 (1.41%)

This chart shows the closing price for MNKD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MannKind Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNKD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNKD

Analyst Price Target is $8.67
▲ +20.87% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for MannKind in the last 3 months. The average price target is $8.67, with a high forecast of $12.00 and a low forecast of $6.50. The average price target represents a 20.87% upside from the last price of $7.17.

This chart shows the closing price for MNKD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in MannKind. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2023
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/5/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersInitiated CoverageOutperform$7.00 ➝ $8.00
8/28/2024OppenheimerBoost TargetOutperform ➝ Outperform$10.00 ➝ $12.00
6/13/2024Rodman & RenshawInitiated CoverageBuy$8.00
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.50
3/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.50
2/28/2024WedbushReiterated RatingOutperform$10.00
2/28/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.50
1/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.50
10/9/2023WedbushInitiated CoverageOutperform
8/14/2023HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $7.50
8/8/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$6.50 ➝ $7.50
7/10/2023Cantor FitzgeraldReiterated RatingOverweight
2/27/2023HC WainwrightBoost Target$6.00 ➝ $7.00
11/9/2022Leerink PartnersBoost TargetOutperform$5.00 ➝ $6.00
2/28/2022HC WainwrightLower TargetBuy$6.50 ➝ $6.00
11/12/2021Cantor FitzgeraldReiterated RatingOverweight
11/11/2021HC WainwrightBoost TargetBuy$6.00 ➝ $6.50
11/9/2021Leerink PartnersReiterated RatingOutperform
8/23/2021HC WainwrightReiterated RatingBuy$6.00
5/13/2021Royal Bank of CanadaInitiated CoverageSector Perform$5.00
3/5/2021Leerink PartnersBoost TargetOutperform$3.00 ➝ $5.00
2/26/2021HC WainwrightBoost Target$2.50 ➝ $6.50
2/24/2021BTIG ResearchBoost TargetBuy$4.00 ➝ $8.00
2/17/2021OppenheimerReiterated RatingBuy$7.00
12/29/2020BTIG ResearchReiterated RatingBuy$4.00
11/5/2020Cantor FitzgeraldReiterated RatingOverweight
7/14/2020OppenheimerReiterated RatingBuy$2.50
6/17/2020BTIG ResearchReiterated RatingBuy$4.00
5/28/2020OppenheimerInitiated CoverageBuy$2.50
5/14/2020HC WainwrightReiterated RatingBuy$2.50
2/26/2020HC WainwrightReiterated RatingBuy$2.50
1/2/2020Leerink PartnersReiterated RatingOutperform
12/23/2019OppenheimerInitiated CoverageOutperform$2.50
11/7/2019HC WainwrightReiterated RatingBuy$2.50
(Data available from 11/2/2019 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/6/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2024
  • 11 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2024
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/3/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/2/2024

Current Sentiment

  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
MannKind logo
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Read More

Today's Range

Now: $7.17
Low: $7.10
High: $7.30

50 Day Range

MA: $6.36
Low: $5.37
High: $7.07

52 Week Range

Now: $7.17
Low: $3.17
High: $7.30

Volume

2,469,425 shs

Average Volume

2,595,796 shs

Market Capitalization

$1.97 billion

P/E Ratio

179.29

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of MannKind?

The following equities research analysts have issued reports on MannKind in the last twelve months: Cantor Fitzgerald, HC Wainwright, Leerink Partners, Leerink Partnrs, Oppenheimer Holdings Inc., Rodman & Renshaw, and Wedbush.
View the latest analyst ratings for MNKD.

What is the current price target for MannKind?

6 Wall Street analysts have set twelve-month price targets for MannKind in the last year. Their average twelve-month price target is $8.67, suggesting a possible upside of 20.9%. Oppenheimer Holdings Inc. has the highest price target set, predicting MNKD will reach $12.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $6.50 for MannKind in the next year.
View the latest price targets for MNKD.

What is the current consensus analyst rating for MannKind?

MannKind currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MNKD will outperform the market and that investors should add to their positions of MannKind.
View the latest ratings for MNKD.

What other companies compete with MannKind?

How do I contact MannKind's investor relations team?

MannKind's physical mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company's listed phone number is (818) 661-5000 and its investor relations email address is [email protected]. The official website for MannKind is www.mannkindcorp.com. Learn More about contacing MannKind investor relations.